Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome
Atreca, Inc. CAMPBELL, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (“Atreca”) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced tha...